PTC Therapeutics | PTCT - Selling And Administration Expenses


PTC Therapeutics reported $80.63M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amgen USD 1.68B 40M Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
Daiichi Sankyo JPY 237.75B 12.21B Sep/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 364.27M 12.54M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026